Article
Cost Profiling of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia Treatment in South Africa: Medicines That Are Still Too Expensive to Swallow
2021-08-06
Abstract excerpt
<h4>Background: </h4> The development of tyrosine kinase inhibitors (TKIs) has improved chronic myeloid leukemia (CML) management and increased CML prevalence due to low mortality rates. CML management is potentially lifelong and expensive and requires pharmacoeconomic approaches and regular review of therapy to ensure that patients obtain cost-effective therapeutic outcomes. Although the introduction of TKIs gene...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 0b79264c-29b6-5bed-9fb9-b85efbcc1f28
- DOI
- 10.21203/rs.3.rs-751789/v1
